Alan Fu

Dr. Fu combines rich experiences in finance with a deep knowledge in science. While at Haitong International and Citigroup he led numerous successful listings of Chinese companies in Hong Kong and the United States, including multiple companies in the healthcare industry. Prior to that, Dr. Fu worked for two law firms－Davis Polk & Wardwell in Hong Kong and Skadden, Arps, Slate, Meagher & Flom in Palo Alto－where he focused on capital markets transactions, including IPOs and bond issuances. Early in his career, he was a scientist at Rigel Pharmaceuticals, a US-based biotechnology company, focusing on research and drug development in the immunology and oncology areas.

Dr. Fu holds a J.D. degree from University of California, Berkeley School of Law, a Ph.D. degree in Molecular Genetics from Washington University School of Medicine in St. Louis, an M.S. degree in Molecular Immunology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences and a B.S. degree in Genetics and Genetic Engineering from Fudan University.